Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-06-2005 | Oral Presentation

TP53 and additional pathways in therapy resistance

Author: PE Lønning

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Resistance to chemotherapy is the main obstacle to cancer cure. Despite encouraging results from preclinical studies, we have limited knowledge regarding mechanisms causing therapy resistance in vivo. We previously identified mutations affecting the L2 and/or L3 domains of the TP53 gene to predict resistance to anthracycline as well as mitomycin therapy [1, 2]. However, while TP53 mutations were significantly associated with therapy failure, we observed tumours resistant to therapy despite harbouring wild-type p53. We also saw responding tumours among those harbouring TP53 mutations affecting the L2 or L3 domains. …
Literature
1.
Aas T, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996, 2: 811-814. 10.1038/nm0796-811.CrossRefPubMed
2.
Geisler S, et al: TP53 gene mutations predict the response to neoadjuvant treatment with FUMI in locally advanced breast cancer. Clin Cancer Res. 2003, 9: 5582-5588.PubMed
3.
Lønning PE: Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance. Trends Mol Med. 2004, 10: 113-118. 10.1016/j.molmed.2004.01.005.CrossRefPubMed
4.
Staalesen V, et al: Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene. 2004, 23: 8535-8544. 10.1038/sj.onc.1207928.CrossRefPubMed
Metadata
Title
TP53 and additional pathways in therapy resistance
Author
PE Lønning
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1075

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Poster Presentation

Breast tumors induced by high-dose radiation display similar genetic profiles

Poster Presentation

Mammary development fate and breast cancer risk

Poster Presentation

Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer

Poster Presentation

Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines

Poster Presentation

Functional characterization of genes involved in the development of breast cancer

Poster Presentation

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits